Research

Cellular

Long-term safety monitoring of new obesity drugs is necessary due to potential serious adverse events.

Practitioners should prioritize safety monitoring for new obesity treatments.

StrongSupportsmedium confidence
These drugs should be evaluated over a wide array of end-points; in particular, long-term safety monitoring is necessary as serious adverse events may appear.
Christoffer Martinussen et al. · Expert Opinion on Emerging Drugs · 2016

Why this rating

The claim is based on expert opinion regarding drug safety.

Source

Emerging drugs for the treatment of obesity

Christoffer Martinussen et al. · Expert Opinion on Emerging Drugs · 2016

DOI 10.1080/14728214.2017.1269744

reviewCited 27×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →